Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.
Abstract
In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.
Overview
CoChat Summary
TL;DR
In the phase III CodeBreaK 300 study, sotorasib 960 mg plus panitumumab did not significantly improve overall survival (OS) versus investigator’s choice in chemorefractory KRAS G12C-mutated metastatic colorectal cancer, with an OS hazard ratio of 0.70 (95% CI, 0.41 to 1.18; P = .20). The authors conclude that the OS trend, higher objective response rate, prior PFS benefit, and safety profile support sotorasib 960 mg-panitumumab as a standard of care in this population.
Key findings
- At a median follow-up of 13.6 months, 82 deaths occurred: 24 in the sotorasib 960 mg-panitumumab arm, 28 in the sotorasib 240 mg-panitumumab arm, and 30 in the investigator’s choice arm. OS HRs versus investigator’s choice were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) for sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) for sotorasib 240 mg-panitumumab.
- Median OS was not reached (95% CI, 8.61 to NE) with sotorasib 960 mg-panitumumab, 11.9 months (95% CI, 7.52 to NE) with sotorasib 240 mg-panitumumab, and 10.3 months (95% CI, 7.00 to NE) with investigator’s choice.
- Updated ORRs were 30.2% (95% CI, 18.3 to 44.3) with sotorasib 960 mg-panitumumab, 7.5% (95% CI, 2.1 to 18.2) with sotorasib 240 mg-panitumumab, and 1.9% (95% CI, 0.0 to 9.9) with investigator’s choice; median DOR was 10.1 months (95% CI, 3.9 to NE) in the sotorasib 960 mg-panitumumab arm.
- No new safety signals were observed. Grade ≥3 treatment-related adverse events occurred in 45.3%, 34.0%, and 45.1% of patients receiving sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator’s choice, respectively.
Methods
- Phase III CodeBreaK 300 randomized 160 adults with KRAS G12C-mutated chemorefractory metastatic colorectal cancer who were KRASG12C inhibitor naïve 1:1:1 to sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator’s choice (n = 54; trifluridine/tipiracil n = 37, regorafenib n = 14).
- OS was a key secondary end point, prespecified at 50% maturity (after approximately 80 deaths); ORR was assessed by blinded independent central review per RECIST v1.1.
- Analysis used the intention-to-treat population; HRs and 95% CIs were estimated with a stratified Cox proportional hazards model, and P values were calculated using a stratified log-rank test.
Limitations
- The paper states the study was not powered to detect a statistically significant OS difference because of the small sample size related to the rarity of this patient population.
- The paper states that post-trial use of KRASG12C inhibitor plus EGFR inhibitor in 27.8% of patients in the investigator’s choice arm could have confounded OS results; an ad hoc sensitivity analysis adjusting for subsequent therapies of interest showed a stratified HR of 0.65 (95% CI, 0.28 to 1.37) for sotorasib 960 mg-panitumumab versus investigator’s choice.
- The paper notes that some prespecified subgroup analyses had small sample sizes and wide CIs; it also states that because statistical significance for OS was not achieved, ORR per BICR was not formally tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
0 Valid · 0 Not valid · 5 Not checked · 21 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Grade ≥3 treatment-related AEs (TRAEs) occurred in 45.3%, 34.0%, and 45.1% of patients receiving sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice, respectively”
§ Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer > RESULTS > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“0.83 (95% CI, 0.49 to 1.39; descriptive two-sided P = .50) with sotorasib 240 mg-panitumumab”
§ Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer > RESULTS > Final OS Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“KRASG12C inhibitor plus anti-EGFR antibody was received by 15 (27.8%) patients in the investigator's choice arm.”
§ Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer > RESULTS > Subsequent Anticancer Therapy and OS Adjustment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The estimated HR for OS was 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20 v statistically significance threshold 0.01875) with sotorasib 960 mg-panitumumab”
- Also stated in: § Abstract · plain
“the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab”
§ Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer > RESULTS > Final OS Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No new safety signals were observed.”
§ Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
9 more claims
Create a free account to see all 26 claims and to verify the 5 references still open.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical trial CodeBreaK 300 phase III, which focused on KRAS G12C, showed that the combination of sotorasib and panitumumab significantly improved the progression-free survival (PFS) compared to standard chemotherapy [58].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The phase III CodeBreaK 300 trial demonstrated improved progression-free survival with the combination of sotorasib and panitumumab compared with standard treatment, supporting the concept of vertical pathway inhibition in KRAS G12C-mutated tumors [58].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“In CodeBreaK 300, sotorasib plus panitumumab improved PFS compared with investigator’s choice therapy in previously treated KRAS G12C-mutant metastatic CRC.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| <65 | 32 (60.4) | 39 (73.6) | 27 (50.0) | | ≥65 | 21 (39.6) | 14 (26.4) | 28 (51.9) |”
§ Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer > RESULTS > Patients and Treatment
Reported 54 · recomputed 55
Citations
Cites
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Self-citationSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Self-citationDasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00772-9 · Cited by 368
Self-citationYaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0217 · Cited by 139
van de Haar, J., Ma, X., Ooft, S. N., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 83
Self-citationTabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102945 · Cited by 18
Self-citation
Cited by
Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 119
Self-citationEmerging landscape of KRAS inhibitors in cancer treatment
Riedl, J. M., Matsubara, H., McNeil, R., Patel, P. S., de la Cruz, F. F., Gulhan, D., & Corcoran, R. B. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.001 · Cited by 53
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 21
Precision Oncology: 2025 in Review
Mai, N., Fernandez, N. C., Drilon, A. E. D. C., & Chakravarty, D. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1784 · Cited by 18
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
Metadata
- Authors
- Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Tran, Q., Cremolini, C., & Fakih, M.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Università Cattolica del Sacro Cuore (IT)
- National Hospital Organization Kyushu Cancer Center (JP)
- Stiftung Charité (DE)
- Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Université Paris Cité, SIRIC CARPEM Comprehensive Cancer Center, Department of Gastroenterology and Digestive Oncology, Hopital Européen Georges Pompidou, Paris, France
- National and Kapodistrian University of Athens (GR)
- GI Oncology Department & Translational Medicine Laboratory, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
- Asan Medical Center (KR)
- National Cancer Center Hospital East (JP)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Royal Marsden Hospital (GB)
- National Taiwan University (TW)
- Amgen (United States) (US)
- University of Pisa (IT)
- City Of Hope National Medical Center (US)
- Corresponding author
- Fakih, Marwan
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2025-07
- Volume
- 43
- Issue
- 19
- Pages
- 2147-2154
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC12199804
- OpenAlex
- W4409350464
- Cited by
- 51
- References
- 8
- Citations by year
- 2026: 39 · 2025: 12
- FWCI
- 20.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Clinical Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C, metastatic colorectal cancer, overall survival, progression-free survival, objective response rate, trifluridine/tipiracil, regorafenib, EGFR inhibition, drug safety
- MeSH terms
- Panitumumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Sulfonamides, Thymine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.